Skye Bioscience $SKYE promised a breakthrough obesity drug—but when human trial results dropped, it didn’t even outperform a placebo. The stock plunged 60% in one day, and now executives are accused of cashing out while pumping up investor expectations. This episode of Sue Wall Street breaks down the lawsuit, the science spin, and what it means for biotech investors, traders, and anyone chasing the next pharma moonshot.

Visit ZLK.com for more info.

Add our WhatsApp Channel.